Daily practice management of myelodysplastic syndromes in france: Data from 907 patients in a one-week cross-sectional study by the groupe francophone des myélodysplasies

Haematologica

Volumn 95, Issue 6, 2010, Pages 892-899

  Kelaidi, Charikleia ^a   Stamatoullas, Aspasia ^a   Beyne Rauzy, Odile ^a   Raffoux, Emmanuel ^a   Quesnel, Bruno ^a   Guerci, Agnes ^a   Dreyfus, François ^a   Brechignac, Sabine ^a   Berthou, Christian ^a   Prebet, Thomas ^a   Hicheri, Yosr ^a   Hacini, Maya ^a   Delaunay, Jacques ^a   Gourin, Marie Pierre ^a   Camo, Jean Marie ^a   Zerazhi, Hacene ^a   Taksin, Anne Laure ^a   Legros, Laurence ^a   Choufi, Bachra ^a   Fenaux, Pierre ^a  

^a AVICENNE HOSPITAL   (France)

Author keywords

Cross sectional study; Erythropoiesis stimulating agents; Erythropoietin; Mds; Outpatient visit

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANDROGEN; ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; AZACITIDINE; CYCLOSPORIN; CYTARABINE; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; LENALIDOMIDE; MERCAPTOPURINE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; ROMIPLOSTIM; THALIDOMIDE; THYMOCYTE ANTIBODY;

5Q- SYNDROME; ADOLESCENT; ADULT; AGE; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; AMBULATORY CARE; ANEMIA; ARTICLE; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG MEGADOSE; ERYTHROCYTE TRANSFUSION; FEMALE; FRANCE; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; IRON CHELATION; IRON OVERLOAD; KARYOTYPE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; OUTPATIENT CARE; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DISEASE MANAGEMENT; ERYTHROCYTE TRANSFUSION; ERYTHROPOIETIN; FEMALE; FRANCE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KARYOTYPING; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; TIME FACTORS; YOUNG ADULT;

EID: 77953186755     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.014357     Document Type: Article

References (30)

1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51(2):189-99.
2. Aul C, Gattermann N, Schneider W. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol. 1992;82(2):358-67.
3. Williamson PJ, Kruger AR, Reynolds PJ, Hamblin TJ, Oscier DG. Establishing the incidence of myelodysplastic syndrome. Br J Haematol. 1994;87(4):743-5.
4. Germing U, Gattermann N, Strupp C, Aivado M, Aul C. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retro-spective analysis of 1600 patients. Leuk Res. 2000;24(12):983-92.
5. Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007;109(8):1536-42.
6. Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood. 2008;112(1):45-52.
7. West RR, Stafford DA, Farrow A, Jacobs A. Occupational and environmental exposures and myelodysplasia: a case-control study. Leuk Res. 1995;19(2):127-39.
8. Nisse C, Haguenoer JM, Grandbastien B, Preudhomme C, Fontaine B, Brillet JM, et al. Occupational and environmental risk factors of the myelodysplastic syndromes in the North of France. Br J Haematol. 2001;112(4):927-35.
9. Hellström-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl IM, Dybedal I, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol. 2003;120(6):1037-46.
10. Kelaidi C, Park S, Brechignac S, Mannone L, Vey N, Dombret H, et al; Groupe Francophone des Myélodysplasies (GFM). Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide. Leuk Res. 2008;32(7):1049-53.
11. Park S, Grabar S, Kelaidi C, Beyne-Rauzy O, Picard F, Bardet V, et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood. 2008;111(2):574-82.
12. Jädersten M, Malcovati L, Dybedal I, Della Porta MG, Invernizzi R, Montgomery SM, et al. Erythropoietin and granulocytecolony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol. 2008; 26(21):3607-13.
13. Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, et al; American Society of Clinical Oncology; American Society of Hematology. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol. 2008;26(1):132-49.
14. Mannone L, Gardin C, Quarre MC, Bernard JF, Vassilieff D, Ades L, et al. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. Br J Haematol. 2006;133(5):513-9.
15. Sekeres MA, Schoonen WM, Kantarjian H, List A, Fryzek J, Paquette R, Maciejewski JP, et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst. 2008;100(21):1542-51.
16. Neukirchen J, Blum S, Kuendgen A, Strupp C, Aivado M, Haas R, et al. Platelet counts and hemorrhagic diathesis in patients with myelodysplastic syndromes (MDS). Eur J Haematol. 2009;83(5):477-82.
17. Martino R, Iacobelli S, Brand R, Brand R, Jansen T, van Biezen A, et al. Myelodysplastic Syndrome subcommittee of the Chronic Leukemia Working Party of the European Blood and Marrow Transplantation Group. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling in myelodysplastic syndromes. Blood. 2006;108(3):836-46.
18. Nachtkamp K, Kündgen A, Strupp C, Giagounidis A, Kobbe G, Gattermann N, et al. Impact on survival of different treatments for myelodysplastic syndromes (MDS). Leuk Res. 2009;33(8):1024-8.
19. Wattel E, Cambier N, Caulier MT, Sautière D, Bauters F, Fenaux P. Androgen therapy in myelodysplastic syndromes with thrombocytopenia: a report on 20 cases. Br J Haematol. 1994;87(1):205-8.
20. Hebbar M, Kaplan C, Caulier MT, Wattel E, Morel P, Wetterwald M, et al. Low incidence of specific anti-platelet antibodies detected by the MAIPA assay in the serum of thrombocytopenic MDS patients and lack of correlation between platelet auto - antibodies, platelet lifespan and response to danazol therapy. Br J Haematol. 1996; 94(1):112-5.
21. Gattermann N. Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Int J Hematol. 2008;88(1):24-9.
22. Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP, et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood. 2007;109(10):4586-8.
23. Fenaux P, Preudhomme C, Hélène Estienne M, Morel P, Laï JL, Gardin C, et al. De novo myelodysplastic syndromes in adults aged 50 or less. A report on 37 cases. Leuk Res. 1990;14(11-12):1053-9.
24. Chang KL, O'Donnell MR, Slovak ML, Dagis AC, Arber DA, Niland JC, et al. Primary myelodysplasia occurring in adults under 50 years old: a clinicopathologic study of 52 patients. Leukemia. 2002;16(4):623-31.
25. Breccia M, Mengarelli A, Mancini M, Biondo F, Gentilini F, Latagliata R, et al. Myelodysplastic syndromes in patients under 50 years old: a single institution experience. Leuk Res. 2005;29(7):749-54.
26. Kuendgen A, Strupp C, Aivado M, Hildebrandt B, Haas R, Gattermann N, et al. Myelodysplastic syndromes under the age of 50 years. J Clin Oncol. 2006;24(34):5358-65.
27. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079-88.
28. Paulsson K, Johansson B. Trisomy 8 as the sole chromosomal aberration in acute myeloid leukemia and myelodysplastic syndromes. Pathol Biol (Paris). 2007;55(1):37-48.
29. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ. The predictive value of hierarchical cytogenetic classification in olderadults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98(5):1312-20.
30. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, et al. Age and acute myeloid leukemia. Blood. 2006;107(9):3481-5.